Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced or Metastatic Non-small Cell Lung Cancer”

585 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 585 results

Testing effectiveness (Phase 2)Looking for participantsNCT07232849
What this trial is testing

A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer
Jiangsu HengRui Medicine Co., Ltd. 100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07285148
What this trial is testing

Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerEGFR MutationMetastatic Lung Cancer+1 more
Beijing Pearl Biotechnology Limited Liability Company 253
Large-scale testing (Phase 3)Study completedNCT00478049
What this trial is testing

Iressa as Second Line Therapy in Advanced NSCLC-Asia

Who this might be right for
NSCLC
AstraZeneca 163
Testing effectiveness (Phase 2)Active Not RecruitingNCT05445843
What this trial is testing

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Who this might be right for
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Novartis Pharmaceuticals 95
Early research (Phase 1)Study completedNCT02457793
What this trial is testing

The Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma
Genentech, Inc. 24
Testing effectiveness (Phase 2)Looking for participantsNCT06567015
What this trial is testing

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Pierre Fabre Medicament 171
Large-scale testing (Phase 3)Active Not RecruitingNCT04765059
What this trial is testing

Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 98
Large-scale testing (Phase 3)Looking for participantsNCT06357533
What this trial is testing

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 675
Testing effectiveness (Phase 2)Looking for participantsNCT06172478
What this trial is testing

HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid TumorMelanomaHead and Neck Cancer+11 more
Daiichi Sankyo 740
Early research (Phase 1)Active Not RecruitingNCT05653882
What this trial is testing

A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors

Who this might be right for
Solid TumorNon Small Cell Lung CancerMelanoma+2 more
Asher Biotherapeutics, Inc. 552
Large-scale testing (Phase 3)Looking for participantsNCT07174908
What this trial is testing

IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

Who this might be right for
Non-Small Cell Lung Cancer
InxMed (Shanghai) Co., Ltd. 400
Testing effectiveness (Phase 2)Study completedNCT01260181
What this trial is testing

Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 30
Large-scale testing (Phase 3)Study completedNCT04923945
What this trial is testing

Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients

Who this might be right for
Non-small Cell Lung Cancer Metastatic
Hutchison Medipharma Limited 203
Testing effectiveness (Phase 2)Active Not RecruitingNCT05801029
What this trial is testing

Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
AstraZeneca 60
Early research (Phase 1)Study completedNCT01325558
What this trial is testing

ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Locally Advanced Malignant NeoplasmMalignant Solid Tumour
Altor BioScience 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06185400
What this trial is testing

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Who this might be right for
Non Small Cell Lung CancerERBB2 Mutation-Related TumorsERBB2 Gene Duplication+1 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 108
Testing effectiveness (Phase 2)Ended earlyNCT00283634
What this trial is testing

Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer

Who this might be right for
NSCLC
Millennium Pharmaceuticals, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT06051695
What this trial is testing

Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Who this might be right for
Solid Tumor, AdultColorectal CancerNSCLC+17 more
A2 Biotherapeutics Inc. 474
Testing effectiveness (Phase 2)Study completedNCT02552121
What this trial is testing

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Who this might be right for
Ovary CancerCervix CancerEndometrium Cancer+4 more
Seagen Inc. 33
Early research (Phase 1)Study completedNCT03821233
What this trial is testing

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Who this might be right for
HER2-expressing Cancers
Zymeworks BC Inc. 112
Load More Results